Newsroom - BioNTech
Welcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Media Downloads. Conference "Working Together to Promote Vaccine Equity for Africa", December 18, 2023. Africa Vaccine Equity Conference 1. Africa Vaccine Equity Conference 2. Africa Vaccine Equity Conference 3.
Pfizer and BioNTech Announce Positive Topline Data for ...
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 …
BioNTech Announces Third Quarter 2024 Financial Results and …
Nov 4, 2024 · BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial results and provide a corporate update for the third quarter of 2024. To access the live conference call via telephone, please register via this link.
BioNTech Beats Expectations, Gives Update on Cancer Drugs
Nov 4, 2024 · Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per diluted share in the period, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84. Sales ...
BioNTech Handily Beats Q3 Expectations, Trims Full-Year
Nov 4, 2024 · In Q3, the company generated $1.36 billion in sales, up from nearly $940 million during the same period in 2023—and far ahead of the consensus forecast, which expected that BioNTech would bring in nearly $652 million in Q3, according to analytics firm Zacks Equity Research. BioNTech reported net profit in the quarter of $216 million—the ...
Pfizer and BioNTech Provide Update on mRNA-based …
Aug 16, 2024 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The ...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
Sep 22, 2021 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older.
Adapted coronavirus vaccines drive BioNTech sales - Yahoo Finance
Mon, Nov 4, 2024, 9:13 AM1 min read. German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron …
Sep 20, 2024 · NEW YORK & MAINZ, Germany, September 20, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human...
BioNTech says FDA lifts partial hold on its cancer drug trial
Aug 19, 2024 · BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
- Some results have been removed